Drug Profile
Neumomir
Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Institute of Biomedical Research Alberto Sols
- Developer Advanced Medical Projects
- Class Antifibrotics; Peptides
- Mechanism of Action Telomerase activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis in Spain (Parenteral)
- 15 Dec 2016 Phase-I clinical trials in Idiopathic pulmonary fibrosis in Spain (Parenteral)